Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/62964
HOW TO ACCELERATE THE SUPPLY OF VACCINES TO ALL POPULATIONS WORLDWIDE? PART I: INITIAL INDUSTRY LESSONS LEARNED AND PRACTICAL OVERARCHING PROPOSALS LEVERAGING THE COVID-19 SITUATION
Streamline
Vaccine
Reliance
Harmonization
COVID-19
Science-based
Risk-based
Digital
Author
McGoldrick, Mic
Gastineau, Thierry
Wilkinson, Diane
Campa, Cristiana
Clercq, Norbert De
Mallia-Milanes, Andrea
Germay, Olivier
Krishnan, Jyothsna
Ooij, M. Van
Thien, Michael P.
Mlynarczyk, Peter J.
Saltus, Edward
Juvin, Philippe
Clenet, Didier
Basso, Ana
Dellepiane, Nora
Pagliusi, Sonia
Stávale, Monique Collaço de Moraes
Sivaramakrishnan, Venkatraman H.
Desai, Samir
Gastineau, Thierry
Wilkinson, Diane
Campa, Cristiana
Clercq, Norbert De
Mallia-Milanes, Andrea
Germay, Olivier
Krishnan, Jyothsna
Ooij, M. Van
Thien, Michael P.
Mlynarczyk, Peter J.
Saltus, Edward
Juvin, Philippe
Clenet, Didier
Basso, Ana
Dellepiane, Nora
Pagliusi, Sonia
Stávale, Monique Collaço de Moraes
Sivaramakrishnan, Venkatraman H.
Desai, Samir
Affilliation
Merck & Co. Inc. Kenilworth. NJ, USA.
Sanofi Pasteur. France.
AstraZeneca. UK.
GSK. UK.
GSK. UK.
GSK. UK.
GSK. UK.
GSK. UK.
Janssen. Belgium.
Merck & Co. Inc. Kenilworth. NJ, USA.
Merck & Co. Inc. Kenilworth. NJ, USA.
Merck & Co. Inc. Kenilworth. NJ, USA.
Sanofi Pasteur. France.
Sanofi Pasteur. France.
Sanofi Pasteur. France.
QRB Consultants Sàrl. Switzerland.
DCVMN International. Switzerland.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Rio de Janeiro, RJ, Brasil.
Bharat Biotech International Ltd. India.
Cadila Healthcare Limited (Zydus Cadila). India.
Sanofi Pasteur. France.
AstraZeneca. UK.
GSK. UK.
GSK. UK.
GSK. UK.
GSK. UK.
GSK. UK.
Janssen. Belgium.
Merck & Co. Inc. Kenilworth. NJ, USA.
Merck & Co. Inc. Kenilworth. NJ, USA.
Merck & Co. Inc. Kenilworth. NJ, USA.
Sanofi Pasteur. France.
Sanofi Pasteur. France.
Sanofi Pasteur. France.
QRB Consultants Sàrl. Switzerland.
DCVMN International. Switzerland.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Rio de Janeiro, RJ, Brasil.
Bharat Biotech International Ltd. India.
Cadila Healthcare Limited (Zydus Cadila). India.
Abstract
The COVID-19 pandemic has shown itself to be an unprecedented challenge for vaccines which are widely recognized as the most important tool to exit this pandemic. We have witnessed vaccine scientists, developers, manufacturers, and stakeholders deliver several vaccines in just about a year. This is an unprecedented achievement in an environment that was not ready to manage such a global public health crisis. Indeed, the pandemic has highlighted some hurdles that need to be addressed in the system in order to streamline the regulatory processes and be in a situation where life-saving pharmaceutical solutions such as vaccines can be delivered quickly and equitably to people across the globe. More precisely, trade-offs had to be made between the need for regulatory flexibility in the requirements for manufacturing and controls to enable rapid availability of large volumes of vaccines vs the increased stringency and the lack of harmonization in the regulatory environment for vaccines globally. It is also characterized by a high heterogeneity in terms of review and approval processes, limiting equitable and timely access. We review and highlight the challenges relating to several topics, including process validation, comparability, stability, post-approval-changes, release testing, packaging, genetically modified organisms and variants. We see four areas for accelerating access to vaccines which provide solutions for the regulatory concerns, (1) science- and risk-based approaches, (2) global regulatory harmonization, (3) use of reliance, worksharing, and recognition processes and (4) digitalization. These solutions are not new and have been previously highlighted. In recent months, we have seen some progress at the health authority level, but still much needs to be done. It is now time to reflect on the first lessons learnt from a devastating pandemic to ultimately ensure quick and wide access to medicines and vaccines for the citizens and patients.
Keywords
Regulatory convergenceStreamline
Vaccine
Reliance
Harmonization
COVID-19
Science-based
Risk-based
Digital
Share